Slideshow
Article
Tuberculosis Management: Returning to Pre-Pandemic Priorities
Slideshow below.
Although we are officially living in a “post-pandemic” world, some long-term global impacts of COVID-19 are still being addressed. We remain off track on global tuberculosis (TB) milestone targets due to halted progress over the last 3 years, with more people going undiagnosed and untreated for TB compared with pre-pandemic years.1 Drug-resistant TB (DR-TB) and multidrug-resistant TB (MDR-TB) continue to represent a major burden, and global spending on TB efforts remains significantly lower than what is needed to reach goals set forth by WHO.1
Despite these challenges, there are also some exciting updates. We now know that TB treatment success rates remained steady during the pandemic (86%), and strong efforts have been made to address DR-TB and MDR-TB via improved treatment options with highly effective, all-oral, shortened treatment regimens, as well as new and promising testing modalities.1-3
1
-
-
-
-
BDQ, bedaquiline; BPaLM, bedaquiline, pretomanid, linezolid, moxifloxacin; FQ, fluoroquinolone; XDR, extensively drug-resistant
-
AFB, acid-fast bacilli; DST, drug susceptibility testing; FL, first-line; LAMP, loop-mediated isothermal amplification; LF-LAM, lateral flow lipoarabinomannan assay; LPA, line-probe assay; NAAT, nucleic acid amplification test; SL, second-line; TB, tuberculosis